ABIVAX's stock dropped more than 40% on June 2, 2026, after rare malignancy cases emerged in its Phase 3 ulcerative colitis drug trial, causing a swift market reaction and a downgrade by Jefferies. The stock fell from about $129.69 to $71 per share midday, with trading volume surging eightfold. This sharp decline erased all gains since mid-2025 and led to a class action lawsuit alleging the company made false or misleading statements. Shareholders who bought ABIVAX shares between June 2, 2021, and June 2, 2026, are encouraged to register for potential recovery and lead plaintiff appointment, with no cost or obligation to participate.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
Aave DAO has proposed an innovative mobile app that integrates fiat currency deposits, self-custody, and decentralized finance (DeFi) lending in one platform. This app allows users to convert fiat to stablecoins and earn yields without needing extern...
Analysts expect Netflix to report $12.6 billion in revenue for Q2 and $51.3 billion for the full year 2026. The operating margin forecast has been revised down from 33% to 32% due to anticipated higher expenses, with an expected operating profit of $...
